|Articles|July 2, 2002

Pharmaceutical Technology

  • Pharmaceutical Technology-07-02-2002
  • Volume 26
  • Issue 7

Congress Adopts New User Fee Program

Author(s)Jill Wechsler

To fund expanded FDA operations designed to streamline drug development and approval, FDA and industry representatives have negotiated the Prescription Drug User Fee Act III.


Related to this article

Quality inspector walking through processing area with stainless tanks and tablet | Image Credit: ©Surachai -stock.adobe.com
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.